NCT04736394View on ClinicalTrials.gov

A Phase 3 Study to Evaluate the Safety and Efficacy of APL-1202 as a Single-agent Oral Treatment Versus Intravesical Instillation of Epirubicin Hydrochloride in naïve Intermediate-risk NMIBC Patients

PHASE3RecruitingINTERVENTIONAL
Enrollment

800

Participants

Timeline

Start Date

September 29, 2021

Primary Completion Date

March 1, 2025

Study Completion Date

December 31, 2025

Conditions
Non-muscle Invasive Bladder Cancer
Interventions
DRUG

APL-1202

APL-1202 single-agent oral treatment

DRUG

Epirubicin Hydrochloride

Epirubicin hydrochloride

Trial Locations (1)

201203

RECRUITING

Fudan University Shanghai Cancer Center, Shanghai

All Listed Sponsors
lead

Jiangsu Yahong Meditech Co., Ltd aka Asieris

INDUSTRY